Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubamatamab Alone or With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
NCT06444880Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2024
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ubamatamab in renal medullary carcinoma (RMC), epithelioid sarcoma (ES), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2024; status: active, not recruiting.
02
Drugs
ubamatamab
03
Conditions
renal medullary carcinoma (RMC)epithelioid sarcoma (ES)
Beyond the preview
Go deeper on NCT06444880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444880.